Diagnostic and prognostic significance of transient ischemic dilation (TID) in myocardial perfusion imaging: A systematic review and meta-analysis

Mohamed Alama, MBBCH, MSc, MRCP (UK), a,e Christopher Labos, MDCM, MSc, b Handel Emery, MBBS, DM, MRCP (UK), c Robert M. Iwanochko, MD, a,e Michael Freeman, MD, d,e Mansoor Husain, MD, a,e,f and Douglas S. Lee, MD, PhD a,b,e,f

a Division of Cardiology, Peter Munk Cardiac Center and the Joint Department of Medical Imaging, Toronto, Canada
b Institute for Clinical Evaluative Sciences, Toronto, Canada
c University of the West Indies, Kingston, Jamaica
d St. Michael’s Hospital, Toronto, Canada
e Department of Medicine, University of Toronto, Toronto, Canada
f Ted Rogers Centre for Heart Research, Toronto, Canada

Received Dec 21, 2016; accepted Jun 6, 2017
doi:10.1007/s12350-017-1040-7

Background. Transient ischemic dilatation (TID) of the left ventricle is a potential marker of high risk obstructive coronary artery disease on stress myocardial perfusion imaging (MPI). There is, however, interstudy variation in the diagnostic performance of TID for identification of severe and extensive coronary disease anatomy, and varied prognostic implications in the published literature.

Methods. We searched MEDLINE, EMBASE, and COCHRANE databases for studies where TID was compared with invasive or CT coronary angiography for evaluation of coronary artery stenosis. Two reviewers independently evaluated and abstracted data from each study. A bivariate random effects model was used to derive pooled sensitivities and specificities, in order to account for correlation between TID in MPI and anatomic disease severity.

Results. A total of 525 articles were reviewed, of which 51 met inclusion criteria. Thirty-one studies contributed to the analysis, representing a total of 2037 patients in the diagnostic meta-analysis and 9003 patients in the review of prognosis. The ratio above which TID was deemed present ranged from 1.13 to 1.38. Pooled sensitivity was 44% (95% CI 30%-60%) and specificity was 88% (95% CI 83%-92%) for the detection of extensive or severe anatomic coronary artery disease. Analysis of outcome data demonstrated increased cardiac event rates in patients with TID and an abnormal MPI. In otherwise normal perfusion, TID is an indicator of poor prognosis in patients with diabetes and/or a history of coronary disease.

Conclusions. Among patients undergoing MPI, the presence of TID is specific for the detection of extensive or severe coronary artery disease. (J Nucl Cardiol 2018;25:724–37.)

Electronic supplementary material The online version of this article (doi:10.1007/s12350-017-1040-7) contains supplementary material, which is available to authorized users. The authors of this article have provided a PowerPoint file, available for download at SpringerLink, which summarises the contents of the paper and is free for re-use at meetings and presentations. Search for the article DOI on SpringerLink.com.
JNC thanks Erick Alexanderson MD, Carlos Guitar MD, and Diego Vences MD, UNAM, Mexico, for providing the Spanish abstract; Haipeng Tang MS, Zhixin Jiang MD, and Weihua Zhou PhD, for providing the Chinese abstract; and Jean-Luc Urbain, MD, PhD, CPE, Past President CANM, Chief Nuclear Medicine, Lebanon VAMC, PA, for providing the French abstract.
Reprint requests: Douglas S. Lee, MD, PhD, Institute for Clinical Evaluative Sciences, University of Toronto, 2075 Bayview Avenue, Room G-106, Toronto, ON M4N 3M5, Canada; dlee@ices.on.ca
1071-3581/$34.00
Copyright © 2017 The Author(s). This article is an open access publication
Antecedentes. La Dilatación Isquémica Transitoria (TID) del ventrículo izquierdo es un marcador potencial de enfermedad arterial coronaria obstructiva de alto riesgo en la fase de estrés del estudio de perfusión miocárdica (EMP). Existe, sin embargo, una variación entre los estudios en el rendimiento diagnóstico de la TID para identificar la severidad y extensión de la enfermedad coronaria anatómica, así como diversas implicaciones pronósticas en la literatura publicadas.

Métodos. Buscamos en las bases de datos de MEDLINE, EMBASE y COCHRANE estudios donde el TID fue comparado con la angiografía coronaria invasiva o por TC (Tomografía Computada) para la evaluación de la estenosis arterial coronaria. Dos revisores evaluaron de forma independiente resumieron y evaluaron los datos de cada estudio. Se utilizó un modelo de efectos aleatorios bivariante para derivar las sensibilidades y especificidades combinadas, a fin de obtener la correlación entre la TID en el EPM y la severidad de la enfermedad anatómica.

Resultados. Se revisaron un total de 525 artículos, de los cuales 51 cumplieron el criterio de inclusión. Treinta y un estudios contribuyeron al análisis, representando un total de 2037 pacientes para el meta-análisis diagnóstico y 9003 pacientes para la revisión del pronóstico. La proporción por encima de la cual la TID se consideró presente osciló entre 1.13 y 1.38. La sensibilidad combinada fue del 44% (IC del 95%: 30-60%) y la especificidad fue del 88% (IC del 95%: 83-92%) para la detección de enfermedad coronaria anatómica extensa o grave. El análisis de los datos de resultado demostró un aumento de las tasas de eventos cardiovasculares en pacientes con TID y un EPM anormal. En la perfusión normal, la TID es un indicador de mal pronóstico en pacientes con diabetes y/o antecedentes de enfermedad coronaria.

Conclusiones. En pacientes que son llevados a un EPM, la presencia de TID es específico para la detección de enfermedad arterial coronaria extensa o severa. (J Nucl Cardiol 2018;25:724–37.)

Chinese Abstract

背景。负荷心肌灌注显像 (MPI) 下，左心室短暂缺血性扩张 (TID) 是高风险冠心病的一个潜在指标。然而，现有的文献对于 TID 诊断严重冠心病以及评价预后的报道不尽相同。

方法。我们利用MEDLINE, EMBASE 和 COCHRANE 数据库，检索了 TID 与冠脉造影或 CT 对比来评估冠状动脉狭窄的文献。两个评审者独立的从每个研究中评估和提取数据。为了了解 TID 和冠状动脉狭窄之间的关联性，用一个二元随机效应模型来获得合并的敏感性和特异性。

结果。总归回顾了 525 篇文献，其中 51 篇符合入选标准。31 个研究有助于本文的分析，在诊断性分析中共 2037 个病人，预后分析中共 9003 病人。TID 定义为比值超过 1.13 ~ 1.38。此时，诊断严重冠心病的合并敏感性是 44% (95% CI; 50-60%), 特异性是 88% (95% CI; 83-92%)。在 MPI 正常的患者中，TID 能够增加心血管事件的发生率; 在 MPI 正常，有糖尿病和/或冠心病的患者中，TID 也是一个独立的预后指标。

结论。在 MPI 患者中，TID 是一个诊断严重冠心病以及评价预后的特异性指标。 (J Nucl Cardiol 2018;25:724–37.)

French Abstract

Contexte. La dilatation ischémique transitoire (DIT) du ventricule gauche mesurée par scintigraphie de perfusion myocardique est un facteur pronostique relativement important dans l'évaluation des risques liés à la maladie coronarienne obstructive. Néanmoins les protocoles d'évaluation de la DIT et la signification des résultats obtenus dans la maladie coronarienne sévère sont assez variables dans les études publiées dans la littérature.

Méthodes. Dans cet article nous avons recherché dans les bases de données MEDLINE, EMBASE et COCHRANE les études où les résultats de la DIT ont été comparés à une angiographie coronarienne obtenue de manière invasive ou par tomodensitométrie. Deux experts ont extrait et évalué indépendamment les données de chaque étude. De manière à tenir compte de la corrélation entre la DIT et la sévérité de la maladie coronarienne une analyse bi-variée des effets aléatoires a été utilisée pour déterminer la sensibilité et la spécificité globales.

Résultats. Au total, 525 articles ont été examinés, dont 51 répondant aux critères d’inclusion. Trente et une études ont contribué à l’analyse, incluant un total de 2037 patients dans la méta-
INTRODUCTION

Myocardial perfusion Imaging (MPI) is an established tool for the diagnosis and risk stratification of patients with coronary artery disease (CAD) for over three decades.\(^1\) MPI has excellent diagnostic and prognostic accuracy and also provides good insight into cardiac function through the interpretation of a variety of perfusion and functional parameters.\(^2,3\) One of these functional parameters is transient ischemic dilation (TID), which has been validated both as a marker of severe and extensive coronary artery disease and as a predictor of cardiac outcomes in independent studies.\(^1,3\)

To date, the pathophysiology of ischemic LV dilatation remains unclear with the theory of subendocardial ischemia gaining the widest acceptance.\(^4,5\) Others cite data supporting ischemia induced physical LV dilation post stress.\(^6,7\) However, several studies have demonstrated that ischemic LV dilatation may be present in patients with normal perfusion and no significant epicardial coronary disease; for example in patients with hypertrophic cardiomyopathy,\(^8\) or in patients with hypertensive heart disease and left ventricular hypertrophy.\(^9\) Therefore the true diagnostic accuracy of TID on MPI is debated and the optimal threshold for its definition remains undefined.

In this study, we conducted a meta-analysis of the diagnostic performance of the presence of TID, compared to anatomical coronary artery assessment. We also conducted a systematic review of the prognostic significance of TID. Both components of our study included patients who underwent either exercise or pharmacologic stress MPI.

METHODS

We employed a systematic search of the MEDLINE, EMBASE, and COCHRANE databases. We searched for English language studies, which examined the diagnostic and/or prognostic accuracy of TID in myocardial perfusion imaging. The search words used were (transient ischemic dilation, transient ischaemic dilation, left ventricular dilation, transient dilation, SPECT, single photon tomography, CT single photon, myocardial perfusion imaging, and myocardial scintigraphy).

Two investigators (MA, HE) independently reviewed the studies and extracted the relevant data including patient demographics, the radiotracer used, the stress modality, and findings on coronary angiography. Where additional data were required to complete the meta-analysis or discrepancies existed, attempts were made to contact the original authors to obtain such information. We excluded studies where: a) there was no coronary arterial anatomic assessment (either invasive coronary angiogram or coronary CT angiography) for comparison, or b) there was no clear documentation of the method used to calculate the ratio above which TID was diagnosed.

The studies identified for inclusion by the two investigators, and data extracted, were reviewed for eligibility and accuracy by a third investigator (DSL). Methodological quality regarding the risk of bias and concerns of applicability was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS 2) tool.\(^10\) QUADAS 2 is a tool used for quality assessment of diagnostic accuracy studies included in systematic reviews and meta-analyses, to assess the risk of bias and applicability for use in systematic reviews. This tool contains 4 domains: patient selection, index test, reference standard, and flow and timing.

Statistical Analysis

Data were extracted to construct 2 × 2 tables, from which the sensitivity and specificity of each study was calculated. The sensitivity and specificity estimates were pooled using a
bivariate random effects model, as recommended by the Cochrane Diagnostic Test Accuracy Working Group. The bivariate model was then used to construct a hierarchical summary receiver operator curve (ROC). A P value <.05 was considered statistically significant. We did not calculate an I² statistic given that it is not an accepted method of measuring heterogeneity between diagnostic studies. Univariate meta-regression was used to assess the significance of key covariates that were likely to affect the diagnostic accuracy of the test. Due to the small number of studies, multivariate meta-regression was not performed as it was likely to be underpowered to detect any differences.

All statistical analyses were conducted using STATA/SE, version 12.0 (Stata Corp LP, College Station, Texas, USA).

RESULTS

Summary of Studies Examining TID

From the initial database search, we identified 525 citations of which 368 articles remained after removing duplicates. After reviewing the titles and abstracts of these records, 317 articles were excluded because they were not relevant to the purpose of the study.

Of the remaining 51 articles, 20 studies were excluded because: (a) there was no evaluation of coronary anatomy (invasive coronary angiogram or CT angiography) for diagnostic studies [n = 11], (b) they included only patients with left ventricular dysfunction and fixed perfusion defects for prognostic studies [n = 1], (c) there was no clear documentation of the method used to calculate the ratio above which TID was diagnosed or only visual assessment of TID was employed [n = 5], (d) incomplete data [n = 2], and (e) duplicate data [n = 1] as shown in Figure 1 (Group Z). These excluded studies are shown in Online Table A. We included 31 studies, of which 23 evaluated TID from a diagnostic perspective. Of these, 13 studies were included in the quantitative meta-analysis (Figure 1, Group A), and 10 studies were not quantitatively synthesized because the patient-level data were only reported in aggregate, and patients could not be separated into TID positive or negative, or severe or non-severe CAD categories (Group C). The quantitative meta-analysis encompassed a total of 2037 patients in the diagnostic evaluation and 9003 patients in the prognostic evaluation (Figure 1). There were 8 studies examining the prognostic significance of TID, which did not report patient-level data and therefore were incorporated in a narrative synthesis (Group B).

Studies of Diagnostic Performance

Characteristics of the 13 studies included in the quantitative meta-analysis are shown in Table 1, and the 10 non-quantitatively analyzed studies are shown in Online Table B. The definition of severe and extensive CAD and software used for TID evaluation are shown in Table 2. Technetium-99 was the most commonly utilized radiotracer (8 studies), followed by TI-201 (2 studies), dual isotope scanning (2 studies), and Rh-82 (1 study). Coronary angiography was performed in 73% of patients. The modulation of stress included exercise (4 studies), pharmacologic stress (6 studies), and both exercise and pharmacologic stress (3 studies). Methodological Quality Assessment using the QUADAS 2 tool revealed that most of the studies included in the meta-analysis demonstrated low risk for bias or concern regarding applicability (Figure 2).

The ratio above which TID was diagnosed ranged from 1.13 to 1.38, with differences noted depending on the tracer used. Using the published TID ratios (as defined by the individual study authors), the sensitivity of TID for the detection of extensive or severe CAD ranged from 21% to 62.5% (see Table 3). One study only showed very low sensitivity (7%). Specificities were higher and demonstrated less variability, ranging from 77% to 98% (Table 3). Bivariate analysis of the 13 studies, which had complete statistical data, revealed a pooled sensitivity of 44% (95% confidence interval [CI] 30%-60%) and a pooled specificity of 88% (95% CI 83%-92%) as shown in Figure 3. The pooled area under the ROC curve was 0.82 (0.78-0.85) for all studies (Figure 4).

Subgroup Analyses for Diagnostic Performance of TID

Subgroup analysis of the technetium studies revealed a pooled sensitivity of 42% (95% CI 23%-63%) and a pooled specificity of 86% (95% CI 78%-92%), which was similar to the overall results above (see Figure 5). Subgroup analyses also demonstrated that studies using exercise as a stressor demonstrated a significantly higher pooled area under the receiver operating characteristic curve (AUC 0.92 vs 0.78, P < .001) for detection of severe CAD compared to studies using pharmacological stressors (Figure 5). In studies that determined the presence of TID qualitatively (instead of quantitatively) the pooled sensitivity was 46% (95% CI 38%-54%) and pooled specificity was 88% (95% CI 79%-93%).

For studies using technetium, the TID range was 1.13-1.31. In these studies, the sensitivity ranged from 34% to 56%, while the specificity ranged from 77% to 98% for detection of severe CAD. Overall sensitivity and specificity were similar for both exercise and pharmacologic technetium studies. Based on univariate meta-regression, the TID ratio cutoff used in various studies had little effect on specificity (P = .99).
However, higher TID ratios resulted in decreased sensitivity ($P < .01$).

**Studies of Prognostic Performance**

Studies evaluating TID as a marker of increased cardiac events are summarized in Table 4. Across studies, the annualized rates of cardiac death or MI ranged from approximately 0.2% to 1% in those with no TID, 2% to 5% in those with TID and normal perfusion, and 5% to 6% among those with TID and ischemia, CAD, or diabetes. De Winter reported that TID was a significant predictor of all-cause mortality even after multivariable adjustment for resting heart rate, beta-adrenoreceptor antagonism, summed rest score, and resting LV ejection fraction.\(^{13}\)

There was heterogeneity of patients in the different prognostic studies of TID. In a study of diabetic patients with TID and ischemia by Petretta et al, the annualized rate of cardiac death or non-fatal MI was 7.2% with post-stress LVEF $\leq 45\%$ and 5.4% when post-stress LVEF was greater than 45%.\(^{14}\) In another study of patients with TID, rates of fatal and non-fatal MI were substantially increased in those who were not revascularized, compared to those who underwent CABG surgery or PCI.\(^{15}\) One study examined patients undergoing MPI prior to non-cardiac surgery and reported high postoperative cardiac event rates: 58% in the presence of TID, 19% with reversible perfusion defects but no TID, and 2% in patients with normal scans. These events were temporally accelerated, with the majority of cardiac events occurring within 4 months postoperatively.\(^{16}\)

**Special Consideration of TID in Patients with Otherwise Normal Perfusion Scans**

The study by Abidov et al demonstrated that TID is an independent prognostic marker for cardiac events in patients with either normal or near-normal MPI.\(^ {17}\) Patients in the highest TID quartile (mean TID ratio of 1.35 $\pm$ 0.14) were older and diabetic. The prognostic
| Study               | Stress/tracer | TID ratio (quant or qual) | # SPECT vs coronary angiography or CTA | Cardiac risk factors                                                                 | Cardiac characteristics |
|---------------------|---------------|---------------------------|---------------------------------------|---------------------------------------------------------------------------------------|--------------------------|
| Xu et al\(^2\) \(2^8\) 62.4 ± 10.0 years 62% men | Exercise Tc 99m | 1.19 (quant) | SPECT: 547 pts, angiography or CTA: 215 pts | Smoking 15%, HTN 59%, DM 18%, Dyslipidemia 50%                                         | Angina 17%               |
| Kinoshita et al\(^2\) \(2^9\) 63.1 ± 7.8 years 87% men | Exercise Tc 99m | 1.012 (quant) | SPECT: 75 pts, angiography or CTA: 55 pts | N/A                                                                                   | N/A                      |
| Petretta et al\(^3\) \(3^0\) 63 ± 9 years 75% men | Ex and Pharm Tc 99m | 1.19 (quant) | SPECT: 692 pts, angiography or CTA: 242 pts | Smoking 47%, HTN 88%, DM 100%, Dyslipidemia 75%                                       | Angina 31%, MI 16%       |
| Weis et al\(^1\) 58 years 78% men | Exercise Tl 201 | 1.12 (quant and qual) | SPECT: 89 pts, angiography or CTA: 89 pts | N/A                                                                                   | N/A                      |
| Chouraqui et al\(^6\) 67 ± 3 years 47% men | Pharm Tl 201 | 1.12 (quant) | SPECT: 73 pts, angiography or CTA: 73 pts | N/A                                                                                   | MI 33%                   |
| Emmett et al\(^3\) \(3^1\) 68 ± 10 years 64% men | Adenosine Tc 99m | 1.19 (quant) | SPECT: 175 pts, angiography or CTA: 55 pts | HTN 82%, DM 81%                                                                  | N/A                      |
| Fallahi et al\(^1\) 56 ± 11 years 23% men | Pharm Tc 99m | 1.17 (quant) | SPECT: 86 pts, angiography or CTA: 38 pts | Smoking 17%, HTN 55%, Dyslipidemia 36%                                              | N/A                      |
| Emmett et al\(^3\) \(3^2\) 72 ± 8 years, 47% men | Ex and Pharm Tc 99m | 1.22 (quant and qual) | SPECT: 103 pts, angiography or CTA: 103 pts | DM 58%                                                                               | N/A                      |
| Marcassa et al\(^5\) 61 ± 8 years % men N/A | Ex and Pharm Tc 99m | 1.24 (quant) | SPECT: 234 pts, angiography or CTA: 186 pts | HTN 33%, DM 5%, Dyslipidemia 42%                                                     | Angina 47%, MI 63%       |
| Rischpler et al\(^2\) \(2^7\) 64 ± 11 years 58% men | Pharm Rb 82 | 1.13 (quant) | SPECT: 265 pts, angiography or CTA: 81 pts | Smoking 26%, HTN 84%, DM 37%, Dyslipidemia 58%                                     | MI 26%, PCI 42%           |
| Mazzanti et al\(^3\) \(3^3\) 66 ± 11 years % men N/A | Exercise Dual | 1.22 (quant) | SPECT: 228 pts, angiography or CTA: 174 pts | N/A                                                                                 | MI 35%, CABG 33%         |
### Table 1. continued

| Study                | Stress/tracer | TID ratio (quant or qual) | # SPECT vs coronary angiography or CTA | Cardiac risk factors | Cardiac characteristics |
|----------------------|---------------|---------------------------|----------------------------------------|----------------------|-------------------------|
| Abidov et al<sup>34</sup> 69 ± 11.4 years 54% men | Pharm Dual     | 1.36 (quant)              | SPECT: 356 pts, angiography or CTA: 179 pts | HTN 70%, DM 31%      | Angina 48%               |
| Golzar et al<sup>12</sup> 62 ± 13 50% men (validation group) | Pharm Tc 99m  | 1.31 (quant)              | SPECT: 647 pts, angiography or CTA: 547 pts | HTN 86%, Dyslipidemia 63% | Chest pain 54% |

*TID*, transient ischemic dilation; *CTA*, CT angiography; *Pts*, patients; *HTN*, hypertension; *DM*, diabetes; *N/A*, not applicable; *MI*, myocardial infarction; *PCI*, percutaneous coronary intervention; *CABG*, coronary artery bypass graft

### Table 2. Definition of CAD severity and software used for TID calculation

| Study                | Definition of severe and extensive CAD | Software used for TID calculation |
|----------------------|----------------------------------------|-----------------------------------|
| Xu et al<sup>28</sup> ≥70% LM or proximal LAD or ≥90% of ≥2 coronary vessels | Cedars Sinai QPS and QGS software |
| Kinoshita et al<sup>29</sup> ≥75% reduction of luminal diameter of ≥2 coronary vessels | GMS-550 A Toshiba workstation |
| Petretta et al<sup>30</sup> ≥70% proximal LAD or ≥90% of ≥2 coronary vessels | Cedars Sinai software |
| Weis et al<sup>1</sup> ≥90% of ≥2 coronary vessels | Formula used for calculation (Mean A EX/Mean A rest) |
| Chouraqui et al<sup>6</sup> ≥90% of 3 coronary vessels | Manual calculation from the anterior view planar images |
| Emmett et al<sup>31</sup> ≥90% of LAD or ≥90% of ≥2 coronary vessels | Emory Cardiac toolbox |
| Fallahi et al<sup>18</sup> Coronary artery index Gensini score used | Cedars Sinai Auto Quant software package |
| Emmett et al<sup>32</sup> ≥90% of LAD or ≥90% of ≥2 coronary vessels | Emory Cardiac toolbox |
| Marcassa et al<sup>5</sup> ≥50% diameter stenosis in major pericardial vessel modified Gensini score | Not specified |
| Rischpler et al<sup>27</sup> Obstructive CAD (Cath/CTA) severity not specified | Card IQ Physio (GE healthcare) |
| Mazzanti et al<sup>33</sup> ≥90% of proximal LAD or ≥90% of ≥2 coronary vessels | Cedars Sinai QPS and QGS software |
| Abidov et al<sup>34</sup> ≥90% of proximal LAD or ≥90% ≥2 vessel disease | Cedars Sinai QPS software |
| Golzar et al<sup>12</sup> ≥70% LM or proximal LAD or ≥90% of ≥2 coronary vessels | 4DM-SPECT version 5.1 |

*CAD*, coronary artery disease; *TID*, transient ischemic dilation; *LM*, left main; *LAD*, left anterior descending; *Cath*, cardiac catheterization; *CTA*, CT angiography
impact of TID with normal myocardial perfusion was modified by the presence of CAD or diabetes, with an increased risk of cardiac death or MI reported in these patients. In a study of diabetes patients with normal post-stress LVEF and no ischemia, the annual event rate was 4.9% in those with TID and 0.2% in those without TID ($P < .001$).

**DISCUSSION**

Our study showed that TID is a specific but not a sensitive marker for detection of severe and extensive CAD with a pooled sensitivity of 44% and pooled specificity of 88%. In the analysis of subgroups, we found that exercise stress resulted in a trend toward higher sensitivity than pharmacologic stress, but specificity was similar. The prognostic studies demonstrated consistently elevated risk when TID was present despite somewhat different populations studied.

This risk was heightened in those with TID and post-stress LVEF $\leq 45\%$, with rates of cardiac death or MI exceeding 7%-year$^{-1}$. Among patients with normal perfusion scans, the presence of TID was associated with increased risk primarily when patients had a history of CAD or DM.

While there are many disparate studies examining diagnostic test performance, few have utilized meta-analytic approaches and summary receiver operating characteristic curves to evaluate the performance of a specific high risk marker such as the presence of TID. Many systematic reviews and meta-analyses were conducted to study the overall diagnostic and prognostic role of different imaging modalities like stress echocardiography, cardiac PET, and coronary CT angiography. However, meta-analyses of specific components of a diagnostic test, such as TID are less commonly encountered. Despite the importance that is imparted to the presence of TID in nuclear cardiology, to our knowledge, this is the first meta-analysis that studied its quantitative diagnostic performance for detection of severe CAD and prognostic performance for prediction of cardiac outcomes.
Mechanistic studies may explain, in part, the reason for the high specificity and low sensitivity of TID. Prior studies have demonstrated that TID results from subendocardial ischemia with apparent LV dilatation due to decrease in the radiotracer uptake in the endocardium.4,5 Others have proposed that TID is a manifestation of LV dilatation post-stress due to ventricular dysfunction.24 Therefore, the presence of TID usually indicates the existence of severe CAD, favoring higher specificity and lower sensitivity for less-critical or less-extensive disease. The diagnostic performance of TID could also be impacted because it may occur in those with hypertensive heart disease, hypertrophic cardiomyopathy, and in some patients undergoing 2-day protocols, with concomitantly normal epicardial coronary vessels.8,9

TID in myocardial perfusion imaging has been proposed as a diagnostic and prognostic marker for the detection of severe and extensive CAD; however, there is variability in the literature on its utility. To our knowledge, this is the first meta-analysis to: (a) examine the range of different ratios above which TID was diagnosed, (b) systematically review the pooled diagnostic performance of TID, and (c) examine the value of TID as a prognostic tool in a systematic review. Our meta-analysis confirms the usefulness of TID in myocardial perfusion imaging as a high risk marker for stress induced myocardial ischemia and its ability to predict future cardiac events. Based on our findings, we propose a modified algorithm approach25 in the presence of TID. Clearly, if both TID and high risk MPI are present, consideration should be given to invasive coronary angiography.25 However, since specificity of TID is high, if TID and non-high risk MPI (SSS < 4) are present in a patient with an intermediate clinical risk (CAD, diabetes, or chronic kidney disease), further non-invasive evaluation may be beneficial.25 Finally, the methodology of quantitative meta-analysis to evaluate other putative high risk diagnostic markers nested within imaging modalities,26 may be useful in future cardiac imaging research.

While meta-analyses are valuable tools for synthesizing the published literature, there are always limitations to such analyses. For example, the different patient populations, techniques, and diagnostic cutoffs all contribute to the clinical heterogeneity of the published literature. While higher TID ratio did affect sensitivity, meta-regression did not identify any other clinical variable that affected the effect estimates. However, due to the relatively small number of publications with interstudy differences in stress modality and tracer employed, the impacts of these factors may have been underrepresented. The majority of studies reported the definition of angiographic severity of coronary artery disease using percent stenosis, except the study by Rischpler.27 We included this study because there were high rates of prior cardiac history (e.g., prior MI, documented CAD, prior coronary revascularization procedures) in the majority of patients and it was the only study that utilized Rb PET.27 However, we did do a sensitivity analysis excluding this study and it revealed that there was no significant change in the diagnostic performance of TID after exclusion of this particular study, with a pooled sensitivity of 47% (31%-63%), specificity of 88% (82%-92%), and an AUC of 0.82 (0.78-0.85).

### Table 3. Diagnostic performance of TID in meta-analyzed studies

| Study          | Sensitivity | Specificity | PPV | NPV |
|----------------|-------------|-------------|-----|-----|
| Xu et al28     | 56          | 90          | 56  | 90  |
| Kinoshita et al29 | 91.4       | 76.9        | 79  | 90  |
| Petretta et al30 | 27.5       | 92.9        | 59.3| 76  |
| Weis et al1    | 60          | 95          | 85  | 82  |
| Chouraqui et al6 | 62.5       | 85          | -   | -   |
| Emmett et al31 | 30.4        | 87.5        | 63.6| 63.6|
| Fallahi et al18 | 66.7       | 70.8        | -   | -   |
| Emmett et al32 | 30          | 93          | 79  | 63  |
| Marcassa et al3 | 37         | 61          | 64  | 34  |
| Rischpler et al27 | 21        | 95.8        | 77  | 63  |
| Mazzanti et al33 | 77         | 92          | -   | -   |
| Abidov et al34 | 73          | 88          | -   | -   |
| Golzar et al12 | 7           | 98          | -   | -   |

Alama et al  
Journal of Nuclear Cardiology®  
May/June 2018
Table 4. Studies included in the systematic review of prognosis

| Study                | Demographics and follow-up | TID ratio (quant or qual), n(%) of pts with TID | Annualized cardiac outcomes |
|----------------------|-----------------------------|-----------------------------------------------|-----------------------------|
| Abidov et al $^{17}$ | Primary study cohort: 1560 pts with normal perfusion: 66.1 ± 12.8 years 50% men Ex and Pharm Dual | 1.21 (quant) n = 390 (25%) | Outcome: cardiac death, MI, or coronary revascularization Normal perfusion (SSS = 0): (a) TID present: 2.4%·year$^{-1}$; (b) No TID (i.e., lowest TID quartile): 0.6%·year$^{-1}$ Normal/near-normal perfusion (SSS 0-3): (a) TID present: 2.2%·year$^{-1}$; (b) Other 3 TID quartiles: 1.0%·year$^{-1}$ |
| Petretta et al $^{14}$ | 672 pts with DM 64 ± 8 years 67% men Ex and Pharm Tc 99m | 1.19 (quant) n = 97 (14%) | Outcome: cardiac death or MI No ischemia + LVEF > 45%: (a) TID present: 4.9%·year$^{-1}$ (b) No TID: 0.21%·year$^{-1}$ Ischemia present + LVEF > 45%: (a) TID present: 5.4%·year$^{-1}$ (b) No TID: 1.9%·year$^{-1}$ Ischemia + LVEF ≤ 45%: (a) TID present: 7.2%·year$^{-1}$ (b) No TID: 3.8%·year$^{-1}$ |
| Doukky et al $^{19}$ | 1236 pts with normal perfusion 58 ± 12 years 52% men Ex and Pharm Tc 99m | 1.16 (Ex) n = 76 (6%) | Outcome: cardiac death or MI Overall: (a) TID present: 2.4%·year$^{-1}$ (b) No TID: 0.4%·year$^{-1}$ DM or CAD: (a) TID present: 5.9%·year$^{-1}$ (b) No TID: 0.2%·year$^{-1}$ |
| Uz zaman et al $^{15}$ | 2689 pts in a single-center 56 ± 9 years 67% men Ex and Pharm Tc 99m | 1.22 (quant) n = 189 (7%) | Outcome: fatal MI (a) TID + not revascularized: 3.3%·year$^{-1}$ (b) TID + revascularized: 1.6%·year$^{-1}$ (c) No TID: not reported Outcome: non-fatal MI (a) TID + not revascularized: 14.2%·year$^{-1}$ (b) TID + revascularized: 3.3%·year$^{-1}$ (c) No TID: not reported |
| Study                      | Demographics and follow-up                                                                 | TID ratio (quant or qual), n(%) of pts with TID | Annualized cardiac outcomes |
|----------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------|-----------------------------|
| Lette et al\(^{16}\)      | 510 total pts; Prognostic cohort: 187 undergoing non-cardiac surgery                       | 1.15 (quant)                                    | Outcome: cardiac death or MI |
| 61 ± 10 years              |                                                                                           | n = 45 (9%)                                     | (a) TID present: 58%·year\(^{-1}\) |
| 55% men Pham               |                                                                                           |                                                 | (b) Reversible defect: 19%·year\(^{-1}\) |
| Ti 201                     |                                                                                           |                                                 | (c) Normal: 2%·year\(^{-1}\)     |
| Lette et al\(^{35}\)      | 753 pts                                                                                   | 1.15 (quant)                                    | Outcome: cardiac death or MI   |
| 62 years Pham Ti 201       |                                                                                           | n = 41 (5%)                                     | (a) TID present: 47.4%·year\(^{-1}\) |
| 57% men                    |                                                                                           |                                                 | (b) Reversible defect: 15.8%·year\(^{-1}\) |
| Thomas et al\(^{36}\)     | 1612 pts                                                                                 | Qualitative                                     | Outcome: cardiac death or MI   |
| 65 ± 12 years Ex and Pharm |                                                                                           |                                                 | Technetium:                   |
| Ti 201                     |                                                                                           |                                                 | (a) TID present: 6%·year\(^{-1}\)  |
| 62% men                     |                                                                                           |                                                 | (b) No TID: 1.5%·year\(^{-1}\)   |
| De winter et al\(^{13}\)  | 294 pts aged ≥ 75 years old                                                               | 1.005 (quant)                                   | Outcome: all-cause death       |
| 78 (IQR: 76-80) years      |                                                                                           | n = 147                                         | (a) TID present: 9.7%·year\(^{-1}\) |
| 54% men Ex and Pharm        |                                                                                           |                                                 | (b) No TID: 5.0%·year\(^{-1}\)   |
| Tc 99m and Dual            |                                                                                           |                                                 |                              |

\(TID\), transient ischemic dilation; \(Ex\), exercise stress; \(Pham\), pharmacologic stress; \(Dual\), dual isotope study; \(MI\), myocardial infarction; \(SSS\), summed stress score; \(DM\), diabetes; \(LVEF\), left ventricular ejection fraction; \(CAD\), coronary artery disease; \(Pts\), patients; \(IQR\), interquartile range
NEW KNOWLEDGE GAINED

The presence of TID has a high pooled area under the receiver operating characteristic curve for the detection of severe and extensive CAD. While sensitivity is low, specificity of TID is high for the detection of severe and extensive CAD.

The rate of cardiac death or MI is increased in those with TID and normal perfusion, primarily amongst those with DM, CAD, or ischemia. Rates of cardiac death or MI appear to be increased further in those with reduced LVEF.

CONCLUSION

In conclusion, in this meta-analysis, we found that transient ischemic dilation during myocardial perfusion imaging is a specific diagnostic marker of severe and extensive coronary artery disease. Transient ischemic dilation is an indicator of poor prognosis, and risks were significantly elevated among those with evidence
suggestive of coronary disease or reduced stress LV ejection fraction. The presence of TID significantly worsens prognosis even among diabetes patients with normal perfusion. Therefore, TID should be considered a high risk marker that may guide clinical management in patients with suspected or known coronary artery disease.

Acknowledgments

This research was supported by a Foundation Grant from the Canadian Institutes of Health Research (Grant # FDN 148446). Dr Lee is supported by a mid-career investigator award from the Heart and Stroke Foundation and is the Ted Rogers Chair in Heart Function Outcomes, a joint Hospital-University Chair of the University Health Network and the University of Toronto. The Institute for Clinical Evaluative Sciences (ICES) is supported in part by a grant from the Ontario Ministry of Health and Long-Term Care. The opinions, results, and conclusions are those of the authors and no endorsement by the Ministry of Health and Long-Term Care or by the Institute for Clinical Evaluative Sciences is intended or should be inferred.

Disclosures

The study authors have no financial conflicts of interest.

Note

This paper is dedicated to the memory of Dr. Michael Freeman (Dec 29, 1948–Sept 3, 2017).

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Weiss AT, Berman DS, Lew AS, Nielsen J, Potkin B, Swan HJ, et al. Transient ischemic dilation of the left ventricle on stress thallium-201 scintigraphy: A marker of severe and extensive coronary artery disease. J Am Coll Cardiol 1987;9:752-9.
2. Iskandrian AS, Heo J, Nguyen T, Lyons E, Paugh E. Left ventricular dilation and pulmonary thallium uptake after single-photon emission computer tomography using thallium-201 during adenosine-induced coronary hyperemia. Am J Cardiol 1990; 66:807-11.
3. Bestetti A, Di Leo C, Alessi A, Triulzi A, Tagliabue L, Tarolo GL. Post-stress end-systolic left ventricular dilation: A marker of endocardial post-ischemic stunning. Nucl Med Commun 2001; 22:685-93.
4. Takeishi Y, Tono-oka I, Ikeda K, Komatani A, Tsuiki K, Yasui S. Dilatation of the left ventricular cavity on dipyridamole thallium-201 imaging: A new marker of triple-vessel disease. Am Heart J 1991;121:466-75.
5. Marcassa C, Galli M, Baroffio C, Campini R, Giannuzzi P. Transient left ventricular dilation at quantitative stress-rest sestamibi tomography: Clinical, electrocardiographic, and angiographic correlates. J Nucl Cardiol 1999;6:397-405.
6. Chouraqui P, Rodrigues EA, Berman DS, Maddahi J. Significance of dipyridamole-induced transient dilation of the left ventricle during thallium-201 scintigraphy in suspected coronary artery disease. Am J Cardiol 1990:66:689-94.
7. Kurata C, Wakabayashi Y, Shouda S, Mikami T, Tawarahara K. Quantification of left ventricular size on exercise thallium-201 single-photon emission tomography. Eur J Nucl Med 1996;23:762-7.
8. Sugihara H, Shiga K, Umanoto I, Harada Y, Katabira T, Nakagawa T, et al. [Assessment of transient dilation of the left ventricular cavity in patients with hypertrophic cardiomyopathy by exercise thallium-201 scintigraphy]. Kaku Igaku 1990;27:1281-9.

Figure 5. ROC curves in different subgroups.
21. Parker MW, Iskandar A, Limone B, Perugini A, Kim H, Jones C, et al. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: A bivariate meta-analysis. Circ Cardiovasc Imaging 2012;5:700-7.

22. Sun Z, Ng KH. Diagnostic value of coronary CT angiography with prospective ECG-gating in the diagnosis of coronary artery disease: A systematic review and meta-analysis. Int J Cardiovasc Imaging 2012;28:2109-19.

23. Pontone G, Andreini D, Bartorelli AL, Bertella E, Mushtaq S, Annoni A, et al. Radiation dose and diagnostic accuracy of multidetector computed tomography for the detection of significant coronary artery stenoses: A meta-analysis. Int J Cardiol 2012;160:155-64.

24. Van Tosh A, Hecht S, Berger M, Roberti R, Luna E, Horowitz SF. Exercise echocardiographic correlates of transient dilation of the left ventricular cavity on exercise thallium-201 SPECT imaging. Chest 1994;106:1725-9.

25. Bourque JM. Contemporary relevance of TID: Based on the company it keeps. J Nucl Cardiol 2015;22:535-8.

26. Gupta A, Baradaran H, Al-Dasuqi K, Knight-Greenfield A, Giambonne AE, Delgado D, et al. Gadolinium enhancement in intracranial atherosclerotic plaque and ischemic stroke: A systematic review and meta-analysis. J Am Heart Assoc 2016;5:e003816. doi:10.1161/JAHA.116.003816.

27. Rischpler C, Higuchi T, Fukushima K, Javadi MS, Merrill J, Nekolla SG, et al. Transient ischemic dilation ratio in 82Rb PET myocardial perfusion imaging: Normal values and significance as a diagnostic and prognostic marker. J Nucl Med 2012;53:723-30.

28. Xu Y, Arsanjani R, Clond M, Hyun M, Lemley M Jr, Fish M, et al. Transient ischemic dilation for coronary artery disease in quantitative analysis of same-day sestamibi myocardial perfusion SPECT. J Nucl Cardiol 2012;19:465-73.

29. Kinoshita N, Sugihara H, Adachi Y, Nakamura T, Azuma A, Kohno Y, et al. Assessment of transient left ventricular dilation on rest and exercise on Tc-99m tetrofosmin myocardial SPECT. Clin Nucl Med 2002;27:349-9.

30. Petretta M, Acampa W, Daniele S, Petretta MP, Plaitano M, Cuocolo A. Transient ischemic dilation in patients with diabetes mellitus: Prognostic value and effect on clinical outcome after coronary revascularization. Circ Cardiovasc Imaging 2013;6:908-15.

31. uz Zaman M, Fatima N, Samad A, Ishaq M, Wali A, Rehman K, et al. Predictive and prognostic values of transient ischemic dilation of left ventricular cavity for coronary artery disease and impact of various managements on clinical outcome using technetium-99m sestamibi gated myocardial perfusion imaging. Ann Nucl Med 2011;25:566-70.

32. Lette J, Lapointe J, Waters D, Cerino M, Picard M, Gagnon A. Transient left ventricular cavitation during dipyridamole-thallium imaging as an indicator of severe coronary artery disease. Am J Cardiol 1990;66:1163-70.

33. Mazzanti M, Germano G, Kiat H, Kavanagh PB, Alexanderson E, et al. Prospective evaluation of the impact of diabetes and left ventricular hypertrophy on the relationship between ischemia and transient ischemic dilation of the left ventricle on single-day adenosine Tc-99m myocardial perfusion imaging. J Nucl Cardiol 2008;15:638-43.

34. Emmett L, Van Gaal WJ, Magee M, Bass S, Ali O, Freedman SB, et al. Identification of severe and extensive coronary artery disease by automatic measurement of transient ischemic dilation of the left ventricle in dual-isotope myocardial perfusion SPECT. J Am Coll Cardiol 1996;27:1612-20.

35. Abidov A, Bax JJ, Hayes SW, Hachamovitch R, Cohen I, Gerlach J, et al. Transient ischemic dilation ratio of the left ventricle is a significant predictor of future cardiac events in patients with otherwise normal myocardial perfusion SPECT. J Am Coll Cardiol 2003;42:1818-25.

36. Mazzanti M, Germano G, Kiat H, Kavanagh PB, Alexanderson E, et al. Transient ischemic dilation ratio in 82Rb PET myocardial perfusion imaging: Normal values and significance as a diagnostic and prognostic marker. J Nucl Med 2012;53:723-30.

37. Xu Y, Arsanjani R, Clond M, Hyun M, Lemley M Jr, Fish M, et al. Transient ischemic dilation for coronary artery disease in quantitative analysis of same-day sestamibi myocardial perfusion SPECT. J Nucl Cardiol 2012;19:465-73.

38. Kinoshita N, Sugihara H, Adachi Y, Nakamura T, Azuma A, Kohno Y, et al. Assessment of transient left ventricular dilation on rest and exercise on Tc-99m tetrofosmin myocardial SPECT. Clin Nucl Med 2002;27:349-9.

39. Petretta M, Acampa W, Daniele S, Petretta MP, Nappi C, Assante R, et al. Transient ischemic dilation in SPECT myocardial perfusion imaging for prediction of severe coronary artery disease in diabetic patients. J Nucl Cardiol 2013;20:45-52.

40. Emmett L, Van Gaal WJ, Magee M, Bass S, Ali O, Freedman SB, et al. Prospective evaluation of the impact of diabetes and left ventricular hypertrophy on the relationship between ischemia and transient ischemic dilation of the left ventricle on single-day adenosine Tc-99m myocardial perfusion imaging. J Nucl Cardiol 2008;15:638-43.

41. Emmett L, Magee M, Freedman SB, Van der Wall H, Bush V, Trieu J, et al. The role of left ventricular hypertrophy and diabetes in the presence of transient ischemic dilation of the left ventricle on myocardial perfusion SPECT images. J Nucl Med 2005;46:1596-601.

42. Mazzanti M, Germano G, Kiat H, Kavanagh PB, Alexanderson E, Freedman JD, et al. Identification of severe and extensive coronary artery disease by automatic measurement of transient ischemic dilation of the left ventricle in dual-isotope myocardial perfusion SPECT. J Am Coll Cardiol 1996;27:1612-20.

43. Abidov A, Bax JJ, Hayes SW, Cohen I, Nishina H, Yoda S, et al. Integration of automatically measured transient ischemic dilation ratio into interpretation of adenosine stress myocardial perfusion SPECT for detection of severe and extensive CAD. J Nucl Med 2004;45:1999-2007.

44. Lette J, Bertrand C, Gossard D, Ruscio O, Cerino M, McNamara D, et al. Long-term risk stratification with dipyridamole imaging. Am Heart J 1995;129:880-6.

45. Thomas GS, Miyamoto MI, Morello AP 3rd, Majmundar H, Thomas JJ, Sampson CH, et al. Technetium 99m sestamibi myocardial perfusion imaging predicts clinical outcome in the community outpatient setting. The Nuclear Utility in the Community (NUC) Study. J Am Coll Cardiol 2004;43:213-23.